• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines

Introduction to 2-2-(benzyloxy)phenylethan-1-amine (CAS No. 80938-36-9)

2-2-(benzyloxy)phenylethan-1-amine, identified by the Chemical Abstracts Service Number (CAS No.) 80938-36-9, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, featuring a unique structural motif comprising a phenyl ring substituted with a benzyloxy group and an amine functional group at the ethyl chain, exhibits promising characteristics that make it a valuable scaffold for the development of novel therapeutic agents.

The molecular structure of 2-2-(benzyloxy)phenylethan-1-amine can be described as a derivative of phenethylamine, where the benzyloxy group at the 2-position of the phenyl ring introduces additional steric and electronic effects that modulate the compound's biological activity. This structural feature has been strategically explored in recent years to develop molecules with enhanced pharmacological properties, particularly in the realm of central nervous system (CNS) drugs and potential immunomodulatory agents.

In recent years, there has been a surge in research focused on identifying and optimizing small-molecule modulators of neurotransmitter systems. The amine moiety in 2-2-(benzyloxy)phenylethan-1-amine suggests potential interactions with monoamine transporters and receptors, which are critical targets for treating neurological disorders such as depression, anxiety, and neurodegenerative diseases. Preliminary studies have indicated that derivatives of this compound may exhibit inhibitory effects on certain monoamine oxidase (MAO) enzymes, which are implicated in the breakdown of neurotransmitters like serotonin and dopamine.

Moreover, the benzyloxy group in the structure of 2-2-(benzyloxy)phenylethan-1-amine contributes to improved solubility and metabolic stability, which are crucial factors for drug candidates intended for oral administration. This characteristic has made it an attractive intermediate in synthetic chemistry for generating libraries of compounds that can be screened for biological activity. High-throughput screening (HTS) campaigns have been employed to identify novel analogs with enhanced affinity and selectivity for specific therapeutic targets.

One of the most compelling aspects of 2-2-(benzyloxy)phenylethan-1-amine is its versatility as a chemical scaffold. Researchers have demonstrated its utility in designing molecules that combine multiple pharmacophores into a single entity, leading to compounds with synergistic effects. For instance, modifications at the benzyloxy substituent have been explored to introduce additional functional groups that can enhance binding interactions with biological targets. These modifications include halogenated aromatic rings, heterocyclic moieties, and other pharmacologically relevant groups that can fine-tune the compound's activity profile.

The synthesis of 2-2-(benzyloxy)phenylethan-1-amine typically involves multi-step organic reactions, starting from readily available precursors such as benzyl alcohol and phenylacetic acid derivatives. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making it feasible to produce sufficient quantities for preclinical studies. Techniques such as palladium-catalyzed cross-coupling reactions have been particularly useful in constructing the complex core structure of this compound with high regioselectivity and yield.

In terms of biological evaluation, early pharmacokinetic studies have revealed that 2-2-(benzyloxy)phenylethan-1-amine exhibits moderate oral bioavailability and reasonable tissue distribution upon administration. These findings are encouraging for further development, as they suggest that the compound may reach therapeutic concentrations in target tissues without significant metabolic degradation. Additionally, preliminary toxicology assessments have shown no overt signs of toxicity at moderate doses, paving the way for more extensive preclinical investigations.

The growing interest in 2-2-(benzyloxy)phenylethan-1-amine is also reflected in its increasing presence in patent literature and scientific publications. Researchers are exploring its potential applications not only in CNS disorders but also in other therapeutic areas such as inflammation and cancer. The ability to modify its structure allows for tailored optimization toward specific disease indications, making it a versatile tool for drug discovery efforts.

Future directions in the study of 2-2-(benzyloxy)phenylethan-1-amine may include exploring its role as a prodrug or co-administered with other therapeutic agents to enhance efficacy or reduce side effects. Computational modeling techniques such as molecular docking and dynamic simulations are being employed to predict how this compound interacts with biological targets at an atomic level. These computational approaches complement experimental data by providing insights into binding affinities and potential mechanisms of action.

Overall, 2-2-(benzyloxy)phenylethan-1-amine (CAS No. 80938-36-9) represents a promising candidate for further pharmaceutical development due to its unique structural features, favorable pharmacokinetic properties, and potential therapeutic applications. As research continues to uncover new insights into its biology and chemistry, this compound is poised to play an important role in addressing unmet medical needs across multiple disease areas.

• 39590-27-7(2-(2-Ethoxyphenyl)ethan-1-amine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)